嵌合抗原受体
医学
淋巴瘤
免疫疗法
临床试验
CD19
肿瘤科
B细胞
内科学
抗原
荟萃分析
细胞因子释放综合征
T细胞
免疫学
免疫系统
美罗华
作者
Na Wang,Yunchong Meng,Yaohui Wu,Jing He,Fang Liu
出处
期刊:Immunotherapy
[Future Medicine]
日期:2021-01-07
卷期号:13 (4): 345-357
被引量:4
标识
DOI:10.2217/imt-2020-0221
摘要
Aim: The aim was to evaluate the efficacy and safety of chimeric antigen receptor T (CAR-T) cell in B-cell non-Hodgkin lymphoma (B-NHL). Materials & methods: A meta-analysis was conducted using eligible clinical trials, which were obtained from electronic medical literature databases. Results: A total of 24 clinical trials with 590 patients were included. The best overall response rate was 66% and complete remission rate was 46%. The incidence rates of cytokine-release syndrome and neurotoxicity (grade ≥ 3) were 9 and 5%, respectively. The various clinical factors were analyzed. Autogenic CAR-T cell may lead to improved efficacy than allogeneic CAR-T cell. CD20 CAR-T cell may show increased efficacy than CD19 CAR-T cell. Conclusion: CAR-T immunotherapy has remarkable efficacy and low toxicity in relapsed/refractory B-NHL.
科研通智能强力驱动
Strongly Powered by AbleSci AI